Penumbra/$PEN
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Penumbra
Domiciled in the US, Penumbra designs, manufactures, and markets an array of thrombectomy and embolization devices and equipment to mechanically remove blood clots. The firm sells mainly to hospitals and physicians. These minimally invasive devices are primarily used in the acute care setting for patients with stroke, pulmonary embolism, deep vein thrombosis, cranial aneurysms, and other vascular diseases.
- Ticker
- $PEN
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 4,700
- Headquarters
- Alameda, United States
- Website
- www.penumbrainc.com
Penumbra Metrics
BasicAdvanced
$13B
78.06
$4.07
0.70
-
Price and volume
Market cap
$13B
Beta
0.7
52-week high
$362.41
52-week low
$221.26
Average daily volume
364K
Financial strength
Current ratio
5.75
Quick ratio
3.633
Long term debt to equity
0.128
Total debt to equity
0.139
Interest coverage (TTM)
96.62%
Profitability
EBITDA (TTM)
204.282
Gross margin (TTM)
67.84%
Net profit margin (TTM)
10.67%
Operating margin (TTM)
12.45%
Effective tax rate (TTM)
21.22%
Revenue per employee (TTM)
$320,000
Management effectiveness
Return on assets (TTM)
6.42%
Return on equity (TTM)
11.37%
Valuation
Price to earnings (TTM)
78.056
Price to revenue (TTM)
8.277
Price to book
8.17
Price to tangible book (TTM)
9.21
Price to free cash flow (TTM)
57.688
Free cash flow yield (TTM)
1.73%
Free cash flow per share (TTM)
5.504
Growth
Revenue change (TTM)
17.55%
Earnings per share change (TTM)
8.81%
3-year revenue growth (CAGR)
17.08%
10-year revenue growth (CAGR)
20.78%
3-year earnings per share growth (CAGR)
74.97%
10-year earnings per share growth (CAGR)
33.31%
What the Analysts think about Penumbra
Analyst ratings (Buy, Hold, Sell) for Penumbra stock.
Analyst projections of the future price of Penumbra stock.
Bulls say / Bears say
Q2 revenue rose 14.9% year on year, with growth in both thrombectomy and embolisation and access; gross margin also improved to 67.9%. This points to demand broadening across Penumbra’s core product lines. (PR Newswire)
THUNDERBOLT received US FDA clearance and a European CE Mark for stroke treatment. That gives Penumbra a route to extend its computer-assisted thrombectomy technology into another major use and geographic market. (Penumbra Inc, Penumbra Inc)
A prospective, multicentre study of 216 patients reported that THUNDERBOLT was safe and effective for large-vessel stroke. Further clinical evidence could help physicians assess and adopt the new system. (Penumbra Inc)
The FDA classified a recall of specific RED 68 catheter lots as Class II after manufacturing issues created a risk of catheter fracture. The recall adds product-quality and patient-safety risk, even though it concerns specified lots rather than the full range. (FDA)
Q2 net income fell to $34.8 million from $45.3 million a year earlier, while operating income was nearly flat despite higher revenue. Higher operating costs and tax reduced the earnings benefit from sales growth. (PR Newswire)
At its Q2 results, Penumbra said it would not provide full-year guidance because of its pending Boston Scientific acquisition. The company also flagged approval and timing risks, as well as possible management distraction and employee departures, leaving investors with less visibility during the transaction. (PR Newswire)
Data summarised monthly by Lightyear AI. Last updated on 3 Oct 2026.
Penumbra Financial Performance
Revenues and expenses
Penumbra Earnings Performance
Company profitability
Upcoming events
No upcoming events
Penumbra News
AllArticlesVideos
Funds containing Penumbra
AllGBPUSDEUR
Fund name | Fund size | $PEN weighting |
|---|---|---|
Amundi S&P 500£500G | £6.6B | 0.43% |
SPDR S&P 400 US Mid Cap$SPY4 | $6.3B | 0.37% |
SPDR S&P 400 US Mid Cap£SPX4 | £4.7B | 0.37% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.20% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | £2.4B | 0.20% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.